EDC built for oncology trials
Native support for longitudinal visits, CTCAE toxicity, RECIST response, repeat biopsies, and survival outcomes.
Common pain points
- •Serial visits hard in generic systems
- •Complex CTCAE toxicity grading
- •AE capture separate from main CRF
- •Unstructured RECIST response
How Trialinx fits
Native longitudinal visits
Baseline + periodic visits (C1D1, C2D1…), repeat forms, tolerance windows.
Preconfigurable scales and scores
Templates for CTCAE v5, RECIST 1.1, ECOG (in progress — feedback welcome).
FDA/EMA audit-trail ready
7 datapoints + indefinite retention cover regulated electronic records.